Results 21 to 30 of about 3,595 (167)
Novel lytic phages improve the antibiofilm activity of dalbavancin, daptomycin, and fosfomycin against vancomycin-resistant enterococci. [PDF]
Microbiol SpectrPeriprosthetic joint infections (PJI) caused by Enterococcus spp., especially vancomycin-resistant strains (VRE), are challenging to treat due to biofilm tolerance and limited antibiotic options.
Fanaei Pirlar R +6 more
europepmc +2 more sources
Revista Española de Quimioterapia, 2021 Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose.
Barberán, José +2 more
+5 more sources
Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience
Antibiotics, 2023 Dalbavancin is a long-acting lipoglycopeptide that is registered for the treatment of acute bacterial skin and skin structure infections, and it is also increasingly used for infections that require prolonged antibiotic treatment.
Dario Cattaneo +9 more
doaj +1 more source
Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
Antibiotics, 2021 Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of ...
Lucia Brescini +16 more
doaj +1 more source
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +2 more sources
Antibiotics, 2022 The antibiotic dalbavancin is approved for intravenous treatment of adults with acute bacterial skin and skin structure infections. This study aimed to observe the use, effectiveness, and safety of dalbavancin in clinical practice in Germany.
Frank Hanses +4 more
doaj +1 more source
Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
BMC Infectious Diseases, 2023 Background Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment.
Anna Lange +2 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2022 : Objective: To evaluate the cost-effectiveness of dalbavancin compared with standard of care (SoC) treatment as daptomycin or teicoplanin in patients with sternal wound infections (SWI).
Renato Pascale +12 more
doaj +1 more source
Antibiotics, 2021 Dalbavancin is a lipoglycopeptide antibiotic that shows potent activity against Gram-positive bacteria. It circumvents vanB-type glycopeptide resistance mechanisms; however, data on the in vitro activity of dalbavancin for Enterococcus faecium (E ...
Robert E. Weber +5 more
doaj +1 more source
In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus
Scientific Reports, 2021 Dalbavancin is a novel glycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It is characterized by a potent activity against numerous Gram-positive pathogens, a long elimination half-life and
Benjamin Jacob +5 more
doaj +1 more source